<p>Tyra Biosciences, Inc.（纳斯达克代码：TYRA - 获取免费报告）在周五的午盘交易中创下了新的 52 周高点。该公司的股价最高达到 24.26 美元，最后交易价格为 23.9230 美元，成交量为 86224 股。该股票此前收盘价为 22.99 美元。</p>
<p>获取 <strong>Tyra Biosciences</strong> 的提醒：</p>
<h2>分析师评级上调和下调</h2>
<p>几位股票分析师对该股发布了报告。HC Wainwright 在 8 月 22 日的研究报告中重申了 “买入” 评级，并对 Tyra Biosciences 的股票设定了 30.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Tyra Biosciences 的 “卖出（d-）” 评级。Wall Street Zen 在 12 月 6 日的报告中将 Tyra Biosciences 的评级从 “卖出” 上调至 “持有”。Oppenheimer 在 9 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 36.00 美元的目标价。最后，Raymond James Financial 在 9 月 2 日的研究报告中开始覆盖 Tyra Biosciences，给予 “强烈买入” 评级，并设定了 35.00 美元的目标价。一位研究分析师对该股给予了强烈买入评级，五位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 33.17 美元。</p>
<p><strong>获取我们关于 TYRA 的最新研究报告</strong></p>
<h2>Tyra Biosciences 股票表现</h2>
<p>该公司的 50 日移动平均价格为 17.93 美元，200 日移动平均价格为 13.55 美元。公司的市值为 13.2 亿美元，市盈率为-13.25，贝塔值为 1.09。</p>
<p>Tyra Biosciences（纳斯达克代码：TYRA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益（EPS）为-0.50 美元，符合市场共识预期的-0.50 美元。整体来看，股票分析师预测 Tyra Biosciences, Inc.在当前财政年度将发布-1.57 的每股收益。</p>
<h2>Tyra Biosciences 的内部交易</h2>
<p>在其他 Tyra Biosciences 的新闻中，董事 Robert J. More 在 11 月 21 日的交易中出售了 246,871 股该公司的股票。股票以平均价格 20.25 美元出售，总价值为 4,999,137.75 美元。出售完成后，该董事直接持有该公司 3,833,425 股股票，估值约为 77,626,856.25 美元。这笔交易代表了他们持股比例的 6.05% 的减少。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。目前 15.20% 的股票由公司内部人士持有。</p>
<h2>对 Tyra Biosciences 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近对该股的持仓进行了调整。Commodore Capital LP 在第二季度将其在 Tyra Biosciences 的持股增加了 226.3%。Commodore Capital LP 现在拥有 3,100,000 股该公司的股票，价值 29,667,000 美元，此前在上个季度购买了额外的 2,150,000 股。Vestal Point Capital LP 在第一季度将其在 Tyra Biosciences 的持股增加了 190.9%。Vestal Point Capital LP 现在拥有 2,879,829 股该公司的股票，估值为 26,782,000 美元，此前在上个季度购买了额外的 1,889,829 股。Caligan Partners LP 在第三季度将其在 Tyra Biosciences 的持股增加了 266.8%。Caligan Partners LP 现在拥有 696,825 股该公司的股票，价值 9,749,000 美元，此前在上个季度购买了额外的 506,875 股。Sio Capital Management LLC 在第二季度将其在 Tyra Biosciences 的持股增加了 94.5%。Sio Capital Management LLC 现在拥有 810,274 股该公司的股票，估值为 7,754,000 美元，此前在上个季度购买了额外的 393,657 股。最后，Balyasny Asset Management L.P.在第二季度将其在 Tyra Biosciences 的持股增加了 139.8%。Balyasny Asset Management L.P.现在拥有 583,386 股该公司的股票，价值 5,583,000 美元，此前在上个季度收购了额外的 340,142 股。机构投资者持有该公司 84.14% 的股票。</p>
<h2>关于 Tyra Biosciences</h2>
<p>（获取免费报告）</p>
<p>Tyra Biosciences（纳斯达克代码：TYRA）是一家临床阶段的精准肿瘤学公司，专注于针对基因定义癌症的小分子疗法的发现和开发。该公司结合生物信息学、分子生物学和药物化学，以识别致癌驱动因子并设计靶向抑制剂。通过利用大规模基因组数据集和功能筛选，Tyra Biosciences 旨在推进满足患者高未满足医疗需求的疗法。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的项目，每个项目针对癌细胞中的特定分子脆弱性。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Tyra Biosciences</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>技术指标如何帮助您找到被超卖的股票</li>
<li>META 在科技下滑中上涨，分析师称特朗普的 AI 命令受到赞扬</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>TL;DR：为什么 Reddit 是新的增长股票之王</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Tyra Biosciences 吗？</h2>
<p>在考虑 Tyra Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tyra Biosciences 并不在名单上。</p>
<p>虽然 Tyra Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TYRA

<p>Tyra Biosciences（纳斯达克代码：TYRA）创下 52 周新高，交易价格最高达到 24.26 美元。分析师的评级各不相同：HC Wainwright 和 Oppenheimer 给予 “买入” 评级，目标价分别为 30 美元和 36 美元，而 Weiss Ratings 则给予 “卖出” 评级。该公司的市值为 13.2 亿美元，第三季度每股收益为（-0.50 美元）。内部人士 Robert J. More 出售了 246,871 股。机构投资者持有该股票的 84.14%。Tyra 专注于针对基因定义癌症的精准肿瘤治疗</p>

<p>Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $24.26 and last traded at $23.9230, with a volume of 86224 shares changing hands. The stock had previously closed at $22.99.</p>
<div class="lb-trans"><p>Tyra Biosciences, Inc.（纳斯达克代码：TYRA - 获取免费报告）在周五的午盘交易中创下了新的 52 周高点。该公司的股价最高达到 24.26 美元，最后交易价格为 23.9230 美元，成交量为 86224 股。该股票此前收盘价为 22.99 美元。</p>
</div><p>Get <strong>Tyra Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tyra Biosciences</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several equities analysts have issued reports on the stock. HC Wainwright restated a &#34;buy&#34; rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, August 22nd. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded Tyra Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Finally, Raymond James Financial started coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a &#34;strong-buy&#34; rating and a $35.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $33.17.</p>
<div class="lb-trans"><p>几位股票分析师对该股发布了报告。HC Wainwright 在 8 月 22 日的研究报告中重申了 “买入” 评级，并对 Tyra Biosciences 的股票设定了 30.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Tyra Biosciences 的 “卖出（d-）” 评级。Wall Street Zen 在 12 月 6 日的报告中将 Tyra Biosciences 的评级从 “卖出” 上调至 “持有”。Oppenheimer 在 9 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 36.00 美元的目标价。最后，Raymond James Financial 在 9 月 2 日的研究报告中开始覆盖 Tyra Biosciences，给予 “强烈买入” 评级，并设定了 35.00 美元的目标价。一位研究分析师对该股给予了强烈买入评级，五位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 33.17 美元。</p>
</div><p><strong>Get Our Latest Research Report on TYRA</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 TYRA 的最新研究报告</strong></p>
</div><h2>Tyra Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Tyra Biosciences 股票表现</h2>
</div><p>The business has a 50 day moving average price of $17.93 and a 200-day moving average price of $13.55. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -13.25 and a beta of 1.09.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 17.93 美元，200 日移动平均价格为 13.55 美元。公司的市值为 13.2 亿美元，市盈率为-13.25，贝塔值为 1.09。</p>
</div><p>Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). As a group, equities analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Tyra Biosciences（纳斯达克代码：TYRA - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益（EPS）为-0.50 美元，符合市场共识预期的-0.50 美元。整体来看，股票分析师预测 Tyra Biosciences, Inc.在当前财政年度将发布-1.57 的每股收益。</p>
</div><h2>Insider Transactions at Tyra Biosciences</h2>
<div class="lb-trans"><h2>Tyra Biosciences 的内部交易</h2>
</div><p>In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the firm's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the sale, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Tyra Biosciences 的新闻中，董事 Robert J. More 在 11 月 21 日的交易中出售了 246,871 股该公司的股票。股票以平均价格 20.25 美元出售，总价值为 4,999,137.75 美元。出售完成后，该董事直接持有该公司 3,833,425 股股票，估值约为 77,626,856.25 美元。这笔交易代表了他们持股比例的 6.05% 的减少。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。目前 15.20% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Tyra Biosciences</h2>
<div class="lb-trans"><h2>对 Tyra Biosciences 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Commodore Capital LP lifted its holdings in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock worth $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter. Vestal Point Capital LP increased its stake in Tyra Biosciences by 190.9% during the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock valued at $26,782,000 after purchasing an additional 1,889,829 shares in the last quarter. Caligan Partners LP raised its holdings in Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company's stock worth $9,749,000 after buying an additional 506,875 shares during the last quarter. Sio Capital Management LLC lifted its stake in shares of Tyra Biosciences by 94.5% in the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company's stock valued at $7,754,000 after buying an additional 393,657 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its position in shares of Tyra Biosciences by 139.8% during the second quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company's stock worth $5,583,000 after acquiring an additional 340,142 shares in the last quarter. Institutional investors own 84.14% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对该股的持仓进行了调整。Commodore Capital LP 在第二季度将其在 Tyra Biosciences 的持股增加了 226.3%。Commodore Capital LP 现在拥有 3,100,000 股该公司的股票，价值 29,667,000 美元，此前在上个季度购买了额外的 2,150,000 股。Vestal Point Capital LP 在第一季度将其在 Tyra Biosciences 的持股增加了 190.9%。Vestal Point Capital LP 现在拥有 2,879,829 股该公司的股票，估值为 26,782,000 美元，此前在上个季度购买了额外的 1,889,829 股。Caligan Partners LP 在第三季度将其在 Tyra Biosciences 的持股增加了 266.8%。Caligan Partners LP 现在拥有 696,825 股该公司的股票，价值 9,749,000 美元，此前在上个季度购买了额外的 506,875 股。Sio Capital Management LLC 在第二季度将其在 Tyra Biosciences 的持股增加了 94.5%。Sio Capital Management LLC 现在拥有 810,274 股该公司的股票，估值为 7,754,000 美元，此前在上个季度购买了额外的 393,657 股。最后，Balyasny Asset Management L.P.在第二季度将其在 Tyra Biosciences 的持股增加了 139.8%。Balyasny Asset Management L.P.现在拥有 583,386 股该公司的股票，价值 5,583,000 美元，此前在上个季度收购了额外的 340,142 股。机构投资者持有该公司 84.14% 的股票。</p>
</div><h2>About Tyra Biosciences</h2>
<div class="lb-trans"><h2>关于 Tyra Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.</p>
<div class="lb-trans"><p>Tyra Biosciences（纳斯达克代码：TYRA）是一家临床阶段的精准肿瘤学公司，专注于针对基因定义癌症的小分子疗法的发现和开发。该公司结合生物信息学、分子生物学和药物化学，以识别致癌驱动因子并设计靶向抑制剂。通过利用大规模基因组数据集和功能筛选，Tyra Biosciences 旨在推进满足患者高未满足医疗需求的疗法。</p>
</div><p>The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的项目，每个项目针对癌细胞中的特定分子脆弱性。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Tyra Biosciences</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>TL;DR: Why Reddit is the New Growth Stock to Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Tyra Biosciences</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
<li>技术指标如何帮助您找到被超卖的股票</li>
<li>META 在科技下滑中上涨，分析师称特朗普的 AI 命令受到赞扬</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>TL;DR：为什么 Reddit 是新的增长股票之王</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tyra Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Tyra Biosciences 吗？</h2>
</div><p>Before you consider Tyra Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tyra Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tyra Biosciences 并不在名单上。</p>
</div><p>While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tyra Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tyra Biosciences（NASDAQ:TYRA）创下 52 周新高 - 以下是发生的事情